- Home
- KITT vs MBRX Comparison
KITT vs MBRX Comparison
Compare KITT & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KITT | MBRX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 8.6M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | KITT | MBRX |
|---|---|---|
| Price | $0.90 | $3.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $105.50 |
| AVG Volume (30 Days) | ★ 20.4M | 621.4K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,688,840.00 | N/A |
| Revenue This Year | $2,936.06 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 95.38 | N/A |
| 52 Week Low | $0.71 | $3.63 |
| 52 Week High | $54.36 | $91.25 |
Technical Indicators
Market Signals| Indicator | KITT | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 51.44 |
| Support Level | $0.86 | $3.74 |
| Resistance Level | $1.02 | $4.24 |
| Average True Range (ATR) | 0.16 | 0.62 |
| MACD | 0.03 | -0.33 |
| Stochastic Oscillator | 16.92 | 6.21 |
Price Performance
Historical ComparisonAbout KITT Nauticus Robotics Inc.
Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.